Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

C N Sternberg, H Dumez, H Van Poppel, I Skoneczna, A Sella, G Daugaard, T Gil, J Graham, P Carpentier, F Calabro, L Collette, D Lacombe, EORTC Genitourinary Tract Cancer Group

Fingeraftryk

Dyk ned i forskningsemnerne om 'Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab